ApoE Polymorphism Is Associated With C-Reactive Protein in
       Low-HDL Family Members and in Normolipidemic Subjects by Kahri, Juhani et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2006, Article ID 12587, Pages 1–5
DOI 10.1155/MI/2006/12587
ResearchCommunication
ApoE Polymorphism Is Associated With C-Reactive Protein in
Low-HDL Family Members and in Normolipidemic Subjects
Juhani Kahri,1 Aino Soro-Paavonen,1,2 Christian Ehnholm,3 and Marja-Riitta Taskinen1
1Division of Cardiology, Department of Internal Medicine, Helsinki University Central Hospital, Haartmaninkatu 4,
PO Box 340, 00029 HUS, Finland
2Baker Medical Research Institute, Melbourne, Victoria, Australia
3Department of Molecular Medicine, Biomedicum, National Public Health Institute, 00251 Helsinki, Finland
Received 30 December 2005; Revised 15 March 2006; Accepted 20 March 2006
The study was aimed to compare inﬂammatory parameters between carriers of apoE4 isoforms (apoE4/3, apoE4/2, and apoE4/4
phenotypes) and those of carrying apoE3 isoform without apoE4 isoform (apoE3/3 phenotypes and apoE2/3 phenotypes). The
concentrations of serum hsCRP, sVCAM-1, sICAM-1, and sE-selectin were measured in 211 subjects from Finnish low-HDL
families and in 157 normolipidemic subjects. The subjects with apoE4 isoform had lower concentrations of serum hsCRP both in
low-HDL family members (p<0.05) and in normolipidemic subjects (p<0.01). The diﬀerences in serum CRP values remained
signiﬁcant after adjustment for age, BMI, smoking status, hypertension, gender, lipoprotein variables, and family number. We
conclude that apoE phenotype has a strong inﬂuence on serum CRP values.
Copyright © 2006 Juhani Kahri et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
A substantial body of evidence indicates, that low-grade in-
ﬂammation in the vascular endothelium promotes athero-
genesis [1, 2]. This is indirectly evidenced by the fact that
several inﬂammatory markers are linked to an increased risk
of atherosclerosis. High-sensitive CRP (hsCRP) has been re-
ported to associate with an increased risk of myocardial in-
farction, stroke, sudden death from cardiac causes, and pe-
ripheral arterial disease [3]. In addition, hsCRP has been
shown to predict the ﬁrst cardiovascular event better than
low-density lipoprotein cholesterol (LDL-C) [3].
Recruitment of inﬂammatory cells from the circulation
and their transendothelial migration is one of the earliest
phases of atherogenesis [3]. Vascular endothelium expresses
cellular adhesion molecules (CAMs) in response to several
inﬂammatory stimuli [4]. The evidence for the role of CAMs
in the pathogenesis of atherosclerosis has emerged from
experimental studies which have demonstrated the focal
expression of adhesion molecules in atherosclerotic plaques
[4–6].
Diﬀerent CAMs have various functions in the vascula-
ture. Selectins and their ligands are involved in the ﬁrst steps
in leukocyte adhesion at sites of endothelial injury as they
mediate the rolling and tethering of leukocytes in the vas-
cular wall [1, 2]. Intercellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion molecule-1 (VCAM-1) induce
ﬁrm adhesion of inﬂammatory cells to the vascular surface
[3]. Overall, both soluble ICAM-1 (sICAM-1) and soluble
VCAM-1 (sVCAM-1) have been linked to increase risk of
atherosclerosis [7–9].
Apolipoprotein E (apoE) is secreted from hepatocytes
andmacrophages.ApoEistransportedinlipoproteins,andit
regulates the hepatic uptake of remnant lipoproteins and fa-
cilitates cholesterol eﬄux from foam cells [10]. In addition,
apoE has a central role in inﬂammation and in mediating
the central nervous system response to injury [11–13]. There
are three common ApoE isoforms, designated E2, E3, and
E4, which are encoded for by distinct alleles on human chro-
mosome 19. ApoE isoforms are distributed in six diﬀerent
phenotypes E2/2, E2/3, E3/3, E4/2, E4/3, and E4/4 [10]. The
presence of E4 isoform is associated with coronary heart dis-
ease[14]andwiththeearlyonsetofAlzheimer’sdisease[15].
Sofar,therearesparsedataonapoEpolymorphisminre-
lation to the parameters of inﬂammation. M¨ antt¨ ari et al [16]
showed that dyslipidemic men with E4/4, E4/3, and E4/2
phenotypes exhibit lower CRP values than men carrying
other apoE phenotypes. In a recent report by M¨ a r ze ta l[ 17],
carriers of apoE2 allele and apoE3/3 homozygotes had sig-
niﬁcantly higher CRP than individuals with the genotypes2 Mediators of Inﬂammation
apoE3/4 and apoE4/4. In dyslipidemic men and women, C-
reactive protein has been reported to be lower in subjects
with one or two copies of E4 allele than in those with zero E4
allele [18]. Paradoxically, E4 allele has been associated with
an enhanced inﬂammatory reaction after cardiopulmonary
bypass [19]. In line, transgenic mice expressing the E4 allele
had greater systemic and brain elevations of proinﬂamma-
tory cytokines than E3 carriers [20].
We hypothesize that the apoE phenotype, as a criti-
cal component in inﬂammatory processes, may inﬂuence
the levels of inﬂammation markers. HDL has been demon-
strated to exhibit antiinﬂammatory properties by inhibit-
ing cytokine induced expression of adhesion molecules [21–
23]. In contrast, acute inﬂammation process may decrease
HDLconcentrationandthuscompromiseitsantiatherogenic
function [24, 25]. Interestingly, recycling of apoE is closely
linked to HDL metabolism [26]. Therefore we studied the
eﬀects of apoE phenotype on the levels of CRP and sCAMs
on a sample of Finnish low-HDL families and in normolipi-
demic subjects.
SUBJECTS AND METHODS
Thestudysubjectswererecruitedaccordingtothestudypro-
tocol as reported previously [27]. To identify the low-HDL
families, ﬁrst degree relatives of the probands were exam-
ined. The family members were coded as aﬀected if their
HDL-C levels were below the 10th percentile cut-oﬀ levels.
If at least two aﬀected subjects were identiﬁed in the family,
all available second-degree relatives and spouses were con-
tacted and included in the study. The blood samples for the
lipid and lipoprotein analysis were taken at the same visit
as the inﬂammation parameters and therefore the lipid and
lipoprotein values in this study represent the values of that
visit,andnotthoseofthescreeningvisit.Altogether211low-
HDL family members and 157 normolipidemic subjects had
measures of their apoE phenotype, hsCRP, and sVCAM-1
concentrations. Seventeen low-HDL subjects had history of
CHD. The normolipidemic group comprised healthy volun-
teers and normolipidemic spouses from the low-HDL fam-
ilies. They were required to have no signs of CHD or dia-
betes, and no lipid lowering medication. The smoking sta-
tus of the patients was categorized into current smokers and
nonsmokers (including exsmokers). Hypertension was de-
ﬁned as self-reported use of antihypertensive drugs, systolic
blood pressure ≥ 140mmHg, or diastolic blood pressure ≥
90mmHg. Estrogen use was deﬁned as any means of es-
trogen administration (oral contraceptives, or oral or trans-
dermal postmenopausal hormone replacement therapy). Ve-
nous blood samples were collected after overnight fasting.
Serum was separated and used for the biochemical measure-
ments. Lipid and lipoprotein measurements were done from
serum as described previously [27]. Serum levels of sICAM-
1, sVCAM-1, and sE-selectin were measured by using com-
mercially available monoclonal antibody-based ELISAs (R
& D Systems, Minneapolis, MN, USA). Serum highly sen-
sitive CRP (hsCRP) was determined by a commercial kit
from Medix Biochemica, Kauniainen, Finland. Subjects with
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determined by the method of Havekes et al [28]. Statisti-
cal comparisons of clinical and biochemical parameters were
performed with SPSS 11.0 for Windows (SPSS Inc., Chigaco,
IL, USA). Data are expressed as mean ± standard error of
mean (SEM). Continuous variables were compared between
two groups by Student t test. Variables with nonnormal dis-
tributionwerelog10-transformedbeforecomparison.P<. 05
was considered to be signiﬁcant (two-tailed). The frequency
distribution between the groups was compared with the Chi-
square test. The correlation coeﬃcients between the bio-
chemical and clinical characteristics were examined by Pear-
son’s correlation for continuous variables. Multiple regres-
sion analysis was performed to determine the relative contri-
bution of diﬀerent variables to hsCRP and sVCAM-1 values.
In the low-HDL group, the subjects came from 47 diﬀerent
families. Ten families had only one subject, and ﬁve fami-
lies had 11–16 subjects. Because the subjects in the present
cohort were not independent, we used the family number
(which indicates belonging to a certain family) as a random
variable. Family-number-adjusted residuals of log CRP and
log VCAM were used in the multiple regression model for
low-HDL family members. Since control subjects were not
related, the family-number adjustment was performed only
in the low-HDL group.
RESULTS
The eﬀects of apoE phenotype was studied by dividing sub-
jects into two subgroups (apoE groups): into the E3 group,
which included E3/2 and E3/3 phenotypes, and into the
E4 group which included E4/2, E4/3, and E4/4 phenotypes.
Clinical and biochemical characteristics of the study subjects
are presented in Table 1.
Table 2 showsthatserumhsCRPvaluesweresigniﬁcantly
lowerintheE4thanintheE3subgroupbothinthelow-HDL
group (P<. 01) and in the normolipidemic group (P<. 05)
after adjustment for age, BMI, serum apoA-I, apoA-II, apoB,
HDL-C, LDL-C, triglycerides, smoking status, hypertension,
and gender in normolipidemic subjects, and after additional
adjustment for family number in the low-HDL group. The
concentration of serum sVCAM-1 was signiﬁcantly lower in
the E4 group than in the E3 group in low-HDL subjects
(P<. 01) but the signiﬁcance disappeared after adjustment
for family number (Table 2). Multiple regression analysis re-
vealed that apoE phenotype was a signiﬁcant predictor of
serum hsCRP values both in low-HDL and normolipidemic
subjects (P = .023 and P = .011, resp) (Table 3). Estrogen
used was also a strong predictor of serum hsCRP concentra-
tion in low-HDL subjects (P = .026) as well as in normolpi-
demic subjects (P = .036) (Table 3).
DISCUSSION
The major ﬁnding of the present study is that subjects
presenting the apoE4 allele have decreased levels of serum
hsCRP. This is an interesting observation, since ApoE plays
a central role in inﬂammation and atherosclerosis. ApoEJuhani Kahri et al 3
Table 1: The clinical characteristics and lipid values of the study subjects.
Low-HDL subjects n = 211 Normolipidemic subjects n = 157
E3 group E4 group E3 group E4 group
N = 140 N = 71 N = 101 N = 56
AGE (y) 41.5 ±1.24 1 .5 ±1.85 1 .8 ±1.14 9 .3 ±1.8
BMI (kg/m2) 25.6 ±0.32 5 .6 ±0.52 4 .9 ±0.42 4 .3 ±0.4
Gender (male/female) 68/72 41/30 45/56 25/31
Smokers (%) 17.1% 31.0%∗ 18.8% 16.1%
Hypertension(%) 27.1% 22.5% 27.7% 17.9%
Estrogen use(%) 17.1% 18.3% 15.8% 19.6%
Cholesterol (mmol/l) 5.05 ±0.07 5.27 ±0.13 5.05 ±0.08 5.13 ±0.11
Triglycerides (mmol/l) 1.32 ±0.06 1.53 ±0.09 1.05 ±0.08 0.95 ±0.04
HDL-cholesterol (mmol/l) 1.30 ±0.04 1.14 ±0.04∗ 1.51 ±0.04 1.51 ±0.05
LDL-cholesterol (mmol/l) 3.15 ±0.08 3.43 ±0.12 3.07 ±0.07 3.19 ±0.10
ApoA-I (mg/dl) 136 ± 2 129 ±2 147 ±3 145 ±3
ApoA-II (mg/dl) 36 ±13 6 ±13 7 ±13 7 ±1
ApoB (mg/dl) 98 ±2 106 ±3‡ 91 ±29 1 ±2
Data are expressed as means ± SEMs.
∗P<. 05, ‡P<. 06 after adjustment for smoking.
Table 2: The concentrations of hsCRP, sVCAM-1, sICAM-1, and sE-SELECTIN in Low-HDL subjects and normolipidemic subjects divided
by apoE subgroups.
Low-HDL subjects n = 211 Normolipidemic subjects n = 157
E3 group n = 140 E4 group n = 71 E3 group n = 101 E4 group n = 56
CRP (mg/l) 1.72 ±0.16 1.14 ±0.17∗∗ 1.29 ±0.14 0.63 ±0.08∗
sVCAM-1 (ng/ml) 540 ±11 478 ±12 496 ±10 494 ± 13
sICAM-1 (ng/ml) 234 ±5 238 ±7 223 ±6 236 ±5
sE-selectin (ng/ml) 49 ±25 0 ±24 5 ±25 0 ± 8
Data are expressed as means ± SEMs. ∗∗P<. 01; ∗P<. 05 for the comparison with the E3 group after adjustment for age, gender, BMI, hypertension, smoking status, and
lipoprotein variables; and family number in the low-HDL group.
Table 3: Multiple regression analysis of predictors of CRP values in low-HDL and normolipidemic subjects.
Low-HDL subjects Normolipidemic subjects
Variable Standardized βPStandardized βP
Age +0.147 .080 +0.244 .003
BMI +0.339 <. 001 +0.315 <. 001
Smoking status +0.129 .057 −0.027 .703
Hypertension +0.024 .732 +0.000 .997
Gender +0.092 .230 −0.154 .878
LDL-C −0.013 .899 +0.064 .524
Triglycerides +0.106 .410 +0.119 .246
HDL-C +0.082 .620 +0.204 .173
ApoA-I +0.008 .961 +0.260 .062
ApoA-II −0.086 .384 +0.062 .473
ApoB +0.057 .676 −0.031 .789
Estrogen use +0.166 .026 +0.161 .036
ApoE grouping −0.150 .023 −0.178 .011
The adjusted multiple R2 is 0.202 (P<. 001) for low-HDL subjects and 0.326 (P<. 001) for normolipidemic subjects when all variables are included. The dependent variable in
low-HDL family members is the family number adjusted residual of log CRP, and in normolipidemic subjects, the dependent variable is log CRP. Variablesw i t hs k e w e d
distribution were log-transformed before entering into the model.4 Mediators of Inﬂammation
knockout mice are especially prone to atherosclerosis [10]
and to die from lipopolysaccharide (LPS)-induced sepsis
[11]. ApoE participates in cholesterol eﬄux, and has been
observed to be recycled from triglyceride-rich lipoproteins
into HDL-particles [10, 26]. In mice, exogenous apoE in-
jection has been demonstrated to decrease the LPS-induced
production of proinﬂammatory cytokines, probable by de-
creasing the release of cytokines from macrophages, which
was accompanied by reduced mortality [11]. CRP and apoE
concentrations are inversely related in obese patients [12].
In addition, human CRP transgene expression has been
shown to cause accelerated atherosclerosis in apolipoprotein
E-deﬁcient mice [13]. Thus, according to these studies, the
roleofapoEininﬂammationandatherosclerosismaybepro-
tective.
Despite the importance of apoE in the inﬂammatory
process, only few studies have linked apoE polymorphisms
to inﬂammatory parameters. In the central nervous system,
apoE4 has been reported to be less eﬀective than apoE3 or
apoE2 at suppressing the activation of microglia in cell cul-
ture models of brain inﬂammation [29]. Transgenic mice
expressing the apoE4 allele have signiﬁcantly greater sys-
temic and brain elevations of proinﬂammatory cytokines
TNF-alpha and IL-6 as compared with their apoE3 coun-
terparts [20]. In the present study, the hsCRP concentra-
tion was signiﬁcantly lower in subjects exhibiting apoE4 al-
lele than in those exhibiting other alleles. Likewise, M¨ antt¨ ari
and associates demonstrated, in a population of 179 dys-
lipidemic Finnish men, that subjects with apoE4/3 pheno-
type had lower mean CRP concentration than those with
apoE3/3 phenotype [16]. In Japanese Americans, CRP val-
ues have been reported to be signiﬁcantly higher in apoE2
carriersthaninapoE3orapoE4carriers,andsimilarbetween
apoE3andapoE4carriers[30].InlinewiththeJapanesedata,
German patients with or without coronary heart disease also
showed higher CRP values in apoE2 carriers than in apoE3/4
heterozygotes or in apoE4/4 homozygotes [17]. However,
CRP was also signiﬁcantly higher in apoE3/3 homozygotes
than in apoE3/4 heterozygotes or in apoE4/4 homozygotes
[17].Similarly,intheCardiovascularHealthStudy[31],CRP
values were lower in apoE4 positive than in apoE4 negative
individuals independently of the amount of used alcohol.
Thus, the present data extend these previous observations
to a cohort of low-HDL family members as well as to nor-
molipidemic subjects.
The mechanisms behind low serum CRP values in apoE4
carriers in this study, and in previous works [16–18, 31]a r e
unclear. Since apoE phenotype remained as a predictor of
hsCRP in multiple regression model, the diﬀerence between
apoE4 and apoE3 groups can not be explained by confound-
ing factors, such as estrogen use. One explanation, origi-
nally suggested by M¨ arz and associates [17], could be that
the metabolism of CRP is related to mevalonate pathway. In
carriers of apoE4, the mevalonate pathway may be down-
regulated resulting in decreased CRP [17].
The observed low serum CRP values in apoE4 carriers in
the present study, and reportedly low CRP values in apoE4
c a r r i e r si np r e v i o u sw o r k s[ 16–18, 31], are perplexing ﬁnd-
ings since apoE4 allele is associated to an increased risk of
atherosclerosis [14]. However, in the present study, the low-
HDL family members within the E4 group had an athero-
genic lipid proﬁle: they had higher concentrations of apoB,
a trend for higher serum triglycerides, and lower concentra-
tion of HDL-C as compared with the E3 group. Thus, the
changes in lipoproteins rather than changes in inﬂammatory
parameters may explain the atherogenity of apoE4 allele.
We conclude that apoE phenotype has a strong inﬂuence
on C-reactive protein. ApoE may be a double-faced protein
having diﬀerent actions in lipid metabolism and inﬂamma-
tion.
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